Roy D, Sadick N, Mangat D
Clinical trial of a novel filler material for soft tissue augmentation of the face containing synthetic calcium hydroxylapatite microspheres. [Journal Article]
Dermatol Surg 2006 Sep; 32(9):1134-9.
BACKGROUND The ideal injectable filler should yield great, long-lasting results, be biocompatible, reliable, safe, easy to use, and inexpensive. Radiesse (Bioform Inc., Franksville, WI) is a synthetic calcium hydroxylaptic filler that has all of the above qualities.
OBJECTIVE To evaluate the effectiveness of Radiese as an injectable filler.
METHODS Eighty-two patients who underwent facial soft tissue augmentation using Radiese from April 2003 to 2004 were enrolled in this study. Pre-filled sterile syringes were used to inject the material into the soft tissues of the face. At the 3 month and six month visits, the physicians and the patients were asked to evaluate the result.
RESULTS Eighty-two patients were injected with Radiesse. The most common area of injection was the melolabial folds. All patients were evaluated during the 3 month follow up visit. There was an overwhelmingly positive response to the look and feel of the implant, averaging 4.6 on a grading scale from 1 to 5, for the patients as well as the injecting physicians. Similar responses were found at the 6 month follow up visit.
CONCLUSION Preliminary data indicate that Radiesse is easy to use and effective with little or no associated morbidity. Deborshi Roy, MD, Neil Sadick, MD, FACP, FAACS, FAAD, FAAPh, and Devinder Mangat, MD, FACS, have indicated no significant interest with commercial supporters.
More from this journal |
